SK pharmteco is proud to support innovation in advanced biopharmaceutical manufacturing through its collaboration with BioCurie on an ARPA-H-backed program focused on scalable, data-driven gene therapy production. As part of this effort, SK pharmteco contributes manufacturing expertise to help advance more efficient and scalable viral vector manufacturing solutions. BioCurie said the award is worth up to $9.3 million, and the project includes SK pharmteco as a collaborator.
This effort reflects SK pharmteco’s commitment to supporting next-generation genomic medicine programs through specialized development and manufacturing capabilities. With experience in complex biologics and viral vector manufacturing support, SK pharmteco works with innovators to help improve process robustness, reduce development risk, and support scalable production. The BioCurie program aims to improve manufacturing through AI-driven modeling and real-world manufacturing data.
As demand grows for reliable, scalable viral vector manufacturing, SK pharmteco continues to invest in the technical expertise, operational capabilities, and strategic collaborations needed to support breakthrough programs and expand access to advanced medicines.
Learn more about BioCurie program.